NASDAQ:ELOX Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis $13.45 +0.25 (+1.89%) As of 10/30/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsSEC Filings About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eloxx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$12.98▼$13.7850-Day Range$12.21▼$20.9852-Week Range$8.20▼$23.40Volume13,988 shsAverage Volume25,648 shsMarket Capitalization$54.34 millionP/E RatioN/ADividend YieldN/APrice Target$37.33Consensus RatingModerate Buy Company Overview Eloxx Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on ribosome modulation therapy, an approach intended to encourage cells to read through certain genetic mutations and restore production of functional proteins. The company’s lead investigational product was ELX-02, a synthetic aminoglycoside designed to promote readthrough of nonsense mutations while seeking to limit the toxicity associated with older aminoglycoside compounds. Eloxx studied ELX-02 in genetic disorders including cystinosis and explored its potential application in other diseases involving nonsense mutations. Eloxx’s programs were directed primarily at rare-disease markets and were investigational rather than established commercial products. The company’s publicly reported operations and pipeline were subject to significant changes, and reliable current information about its leadership, corporate status, and active programs is limited.AI Generated. May Contain Errors. Read More Eloxx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreELOX MarketRank™: 3.97973762826 of 5 starsEloxx Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 100th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEloxx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEloxx Pharmaceuticals has a consensus price target of $37.33, representing about 177.6% upside from its current price of $13.45.Amount of Analyst CoverageEloxx Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eloxx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($2.61) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eloxx Pharmaceuticals is -8.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eloxx Pharmaceuticals is -8.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.38% of the float of Eloxx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEloxx Pharmaceuticals has a short interest ratio ("days to cover") of 1.78, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eloxx Pharmaceuticals has recently decreased by 23.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEloxx Pharmaceuticals does not currently pay a dividend.Dividend GrowthEloxx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.12 News SentimentEloxx Pharmaceuticals has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Eloxx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for ELOX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders25.90% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.Read more about Eloxx Pharmaceuticals' insider trading history. Receive ELOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELOX Stock News HeadlinesEloxx Pharmaceuticals, Inc. Announces FDA Clearance Of Investigational New Drug Application For Exaluren In Nonsense-Mutation Autosomal Dominant Polycystic Kidney DiseaseOctober 31 at 2:32 AM | marketscreener.comMGuggenheim Issues Pessimistic Forecast for Eloxx Pharmaceuticals (NASDAQ:ELOX) Stock PriceOctober 30 at 2:12 AM | americanbankingnews.comCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This past May, flooding hit the same complex again, and in July Cigar Lake went down a second time, disrupting the world's largest high-grade uranium mine. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.October 31 at 1:00 AM | Digest Publishing (Ad)Eloxx Gains FDA Clearance For Exaluren Phase 2 Trial In Genetic Kidney DiseaseOctober 29 at 2:59 PM | rttnews.comEloxx Pharmaceuticals, Inc.: Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKDOctober 29 at 9:59 AM | finanznachrichten.deEloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKDOctober 29 at 8:00 AM | prnewswire.comEloxx Pharmaceuticals appoints Geno J Germano to board on October 19, 2026 and announces clinical updateOctober 22, 2026 | msn.comEloxx Pharmaceuticals, Inc. Finalizes Express Phase 2 Global Study Design in Nonsense-Mutation ADPKDOctober 21, 2026 | marketscreener.comMSee More Headlines ELOX Stock Analysis - Frequently Asked Questions How have ELOX shares performed this year? Eloxx Pharmaceuticals' stock was trading at $0.0121 on January 22, 2026. Since then, ELOX stock has increased by 111,057.0% and is now trading at $13.45. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) released its earnings results on Tuesday, August, 11th. The company reported ($0.66) earnings per share for the quarter. When did Eloxx Pharmaceuticals' stock split? Eloxx Pharmaceuticals shares reverse split on Monday, June 1st 2026.A 1-11 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. When did Eloxx Pharmaceuticals IPO? Eloxx Pharmaceuticals (ELOX) raised $33 million in an initial public offering on Tuesday, June 9th 2026. The company issued 2,975,000 shares at a price of $11.00 per share. When does the company's lock-up period expire? Eloxx Pharmaceuticals's lock-up period expires on Monday, December 7th. Eloxx Pharmaceuticals had issued 2,975,000 shares in its initial public offering on June 9th. The total size of the offering was $32,725,000 based on an initial share price of $11.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today10/31/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ELOX CIK1035354 Webwww.eloxxpharma.com Phone781-577-5300Fax908-864-4440Employees7Year FoundedN/APrice Target and Rating Average Price Target for Eloxx Pharmaceuticals$37.33 High Price Target$40.00 Low Price Target$32.00 Potential Upside/Downside+177.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.74 Quick Ratio3.74 Sales & Book Value Annual Sales$6.36 million Price / Sales8.54 Cash FlowN/A Price / Cash FlowN/A Book Value($85.17) per share Price / Book-0.16Miscellaneous Outstanding Shares4,040,000Free Float2,991,000Market Cap$54.34 million OptionableN/A Beta-1,960.42 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ELOX) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
